Ownership and insider activity for Emergent BioSolutions Inc. (EBS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations.
Price
| Price | $6.75 |
| Market Cap | $348M |
| Exchange | NYSE |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-05 | Duatschek Stephanie | |||
| 2026-08-05 | Duatschek Stephanie | 6,772 | $400K | |
| 2026-08-05 | Duatschek Stephanie | 7,250 | $300K | |
| 2026-08-05 | Duatschek Stephanie | 2,308 | $27K | |
| 2026-08-05 | Duatschek Stephanie | 9,231 | $77K | |
| 2026-08-05 | Duatschek Stephanie | 125,000 | $291K | |
| 2026-08-05 | Duatschek Stephanie | 62,500 | $362K | |
| 2026-08-05 | Duatschek Stephanie | 44,834 | $403K | |
| 2026-07-01 | Williams Paul Anthony | S-Sale | 3,000 | $25K |
| 2026-06-08 | Williams Paul Anthony | F-InKind | 694 | $6K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $271.5M | $178.3M | $112.2M | $168.0M | $621.3M | $576.3M | $642.6M | $111.7M | $99.5M | $205.4M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $148.5M | $146.1M | $262.5M | $275.3M | $230.9M | $278.9M | $159.2M | $191.0M | $154.5M | $84.2M |
| Inventory | $74.0M | $142.8M | $205.8M | $222.5M | $307.0M | $344.5M | $350.7M | $328.9M | $311.7M | $343.4M |
| Total Current Assets | $510.2M | $485.4M | $620.8M | $686.2M | $1.20B | $1.27B | $1.21B | $679.5M | $598.7M | $662.5M |
| Property, Plant & Equipment | $376.4M | $407.2M | $510.2M | $567.0M | $675.1M | $828.4M | $837.0M | $399.0M | $270.6M | $205.4M |
| Goodwill | $41.0M | $49.1M | $259.7M | $266.6M | $266.7M | $224.9M | $218.2M | 0 | 0 | 0 |
| Intangible Assets | $33.9M | $119.6M | $811.6M | $741.9M | $663.1M | $604.6M | $728.8M | $566.6M | $501.5M | $436.5M |
| Total Assets | $970.1M | $1.07B | $2.23B | $2.33B | $2.88B | $2.96B | $3.17B | $1.82B | $1.39B | $1.32B |
| Accounts Payable | $34.6M | $41.8M | $80.7M | $94.8M | $136.1M | $128.9M | $103.5M | $112.2M | $60.9M | $55.6M |
| Short-term Debt | $20.0M | 0 | $10.1M | $16.4M | $39.5M | $37.4M | $963.1M | $413.7M | $2.7M | 0 |
| Total Current Liabilities | $105.9M | $100.1M | $200.4M | $216.3M | $384.5M | $374.0M | $1.23B | $651.3M | $162.4M | $132.2M |
| Long-term Debt | $248.1M | $13.5M | $784.5M | $798.4M | $850.3M | $809.4M | $448.5M | $446.5M | $663.7M | $572.1M |
| Total Liabilities | $373.9M | $157.9M | $1.22B | $1.24B | $1.44B | $1.35B | $1.78B | $1.17B | $906.9M | $796.0M |
| Retained Earnings | $254.5M | $337.1M | $367.3M | $421.8M | $726.9M | $950.3M | $738.7M | -$21.8M | -$212.4M | -$159.8M |
| Total Equity | $596.2M | $912.3M | $1.01B | $1.09B | $1.45B | $1.61B | $1.39B | $649.3M | $482.8M | $522.6M |
| Total Debt | $268.1M | $13.5M | $794.6M | $836.9M | $923.0M | $871.0M | $1.43B | $860.2M | $676.1M | $572.1M |
| Net Debt | -$3.4M | -$164.8M | $682.4M | $668.9M | $301.7M | $294.7M | $783.8M | $748.5M | $576.6M | $366.7M |
| Working Capital | $404.4M | $385.3M | $420.4M | $469.9M | $811.4M | $895.9M | -$18.5M | $28.2M | $436.3M | $530.3M |
Financial Health
| Debt / Equity | 1.70 |
| Current Ratio | 5.42 |
Profitability
| Return on Equity | -35.91% |
| Return on Invested Capital | -5.47% |
| Return on Assets | -15.83% |
| Gross Margin | 49.40% |
| Operating Margin | -7.06% |
| Net Margin | -22.96% |
Related companies: AQST · CMPS · CRVS · ESPR · OLMA · ORGO · PRTA
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of EBS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks